{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:03:14Z","timestamp":1784188994749,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,16]]},"DOI":"10.7759\/cureus.112759","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T07:04:22Z","timestamp":1784185462000},"source":"Crossref","is-referenced-by-count":0,"title":["Multi-ancestry Transcriptome-Wide Association Study (TWAS)-Informed Prioritization of Antipsychotic Metabolic Risk: Evaluation of GLP1R as a Shared Mechanistic Link"],"prefix":"10.7759","author":[{"given":"Ngo","family":"Cheung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","author":"American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity","year":"2004","unstructured":"American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004, 27:596-601. 10.2337\/diacare.27.2.596","journal-title":"Diabetes Care"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert M","year":"2011","unstructured":"De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011, 8:114-26. 10.1038\/nrendo.2011.156","journal-title":"Nat Rev Endocrinol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn M","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al.. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019, 394:939-51. 10.1016\/S0140-6736(19)31135-3","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht S","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, et al.. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013, 382:951-62. 10.1016\/S0140-6736(13)60733-3","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519001-00001","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19 Suppl 1","author":"Newcomer JW","year":"2005","unstructured":"Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005, 19 Suppl 1:1-93. 10.2165\/00023210-200519001-00001","journal-title":"CNS Drugs"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger T","year":"2020","unstructured":"Pillinger T, McCutcheon RA, Vano L, et al.. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020, 7:64-77. 10.1016\/S2215-0366(19)30416-X","journal-title":"Lancet Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890424841","article-title":"","author":"American Psychiatric Association","year":"2020","unstructured":"American Psychiatric Association. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition. American Psychiatric Association Publishing, Washington, D.C.; 2020. 10.1176\/appi.books.9780890424841"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116645254","article-title":"BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment","volume":"30","author":"Cooper SJ","year":"2016","unstructured":"Cooper SJ, Reynolds GP, Barnes T, et al.. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. 2016, 30:717-48. 10.1177\/0269881116645254","journal-title":"J Psychopharmacol"},{"key":"ref9","article-title":"World Health Organization. Management of Physical Health Conditions in Adults With Severe Mental Disorders: WHO Guidelines","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Management of Physical Health Conditions in Adults With Severe Mental Disorders. World Health Organization, Geneva, Switzerland; 2018. https:\/\/www.who.int\/publications\/i\/item\/978-92-4-155038-3."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07019-6","article-title":"Genetic drivers of heterogeneity in type 2 diabetes pathophysiology","volume":"627","author":"Suzuki K","year":"2024","unstructured":"Suzuki K, Hatzikotoulas K, Southam L, et al.. Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. Nature. 2024, 627:347-57. 10.1038\/s41586-024-07019-6","journal-title":"Nature"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3367","article-title":"A gene-based association method for mapping traits using reference transcriptome data","volume":"47","author":"Gamazon ER","year":"2015","unstructured":"Gamazon ER, Wheeler HE, Shah KP, et al.. A gene-based association method for mapping traits using reference transcriptome data. Nat Genet. 2015, 47:1091-8. 10.1038\/ng.3367","journal-title":"Nat Genet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03621-1","article-title":"Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics","volume":"9","author":"Barbeira AN","year":"2018","unstructured":"Barbeira AN, Dickinson SP, Bonazzola R, et al.. Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics. Nat Commun. 2018, 9:1825. 10.1038\/s41467-018-03621-1","journal-title":"Nat Commun"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1143","article-title":"DGIdb 3.0: a redesign and expansion of the drug-gene interaction database","volume":"46","author":"Cotto KC","year":"2018","unstructured":"Cotto KC, Wagner AH, Feng YY, et al.. DGIdb 3.0: a redesign and expansion of the drug-gene interaction database. Nucleic Acids Res. 2018, 46:D1068-73. 10.1093\/nar\/gkx1143","journal-title":"Nucleic Acids Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa1084","article-title":"Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts","volume":"49","author":"Freshour SL","year":"2021","unstructured":"Freshour SL, Kiwala S, Cotto KC, et al.. Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids Res. 2021, 49:D1144-51. 10.1093\/nar\/gkaa1084","journal-title":"Nucleic Acids Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv1165","article-title":"DGIdb 2.0: mining clinically relevant drug-gene interactions","volume":"44","author":"Wagner AH","year":"2016","unstructured":"Wagner AH, Coffman AC, Ainscough BJ, et al.. DGIdb 2.0: mining clinically relevant drug-gene interactions. Nucleic Acids Res. 2016, 44:D1036-44. 10.1093\/nar\/gkv1165","journal-title":"Nucleic Acids Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio LL","year":"2007","unstructured":"Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007, 132:2131-57. 10.1053\/j.gastro.2007.03.054","journal-title":"Gastroenterology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker DJ","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018, 27:740-56. 10.1016\/j.cmet.2018.03.001","journal-title":"Cell Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller TD","year":"2019","unstructured":"M\u00fcller TD, Finan B, Bloom SR, et al.. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019, 30:72-130. 10.1016\/j.molmet.2019.09.010","journal-title":"Mol Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13734","article-title":"Glucagon-like peptide agonists for weight management in antipsychotic-induced weight gain: a systematic review and meta-analysis","volume":"150","author":"Bak M","year":"2024","unstructured":"Bak M, Campforts B, Domen P, van Amelsvoort T, Drukker M. Glucagon-like peptide agonists for weight management in antipsychotic-induced weight gain: a systematic review and meta-analysis. Acta Psychiatr Scand. 2024, 150:516-29. 10.1111\/acps.13734","journal-title":"Acta Psychiatr Scand"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial","volume":"74","author":"Larsen JR","year":"2017","unstructured":"Larsen JR, Vedtofte L, Jakobsen MS, et al.. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry. 2017, 74:719-28. 10.1001\/jamapsychiatry.2017.1220","journal-title":"JAMA Psychiatry"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13522","article-title":"Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis","volume":"21","author":"Siskind D","year":"2019","unstructured":"Siskind D, Hahn M, Correll CU, et al.. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis. Diabetes Obes Metab. 2019, 21:293-302. 10.1111\/dom.13522","journal-title":"Diabetes Obes Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/nrm782","article-title":"Regulated transport of the glucose transporter GLUT4","volume":"3","author":"Bryant NJ","year":"2002","unstructured":"Bryant NJ, Govers R, James DE. Regulated transport of the glucose transporter GLUT4. Nat Rev Mol Cell Biol. 2002, 3:267-77. 10.1038\/nrm782","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2007.03.006","article-title":"The GLUT4 glucose transporter","volume":"5","author":"Huang S","year":"2007","unstructured":"Huang S, Czech MP. The GLUT4 glucose transporter. Cell Metab. 2007, 5:237-52. 10.1016\/j.cmet.2007.03.006","journal-title":"Cell Metab"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.REV119.008351","article-title":"Thirty sweet years of GLUT4","volume":"294","author":"Klip A","year":"2019","unstructured":"Klip A, McGraw TE, James DE. Thirty sweet years of GLUT4. J Biol Chem. 2019, 294:11369-81. 10.1074\/jbc.REV119.008351","journal-title":"J Biol Chem"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3159","article-title":"PPAR\u03b3 signaling and metabolism: the good, the bad and the future","volume":"19","author":"Ahmadian M","year":"2013","unstructured":"Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM. PPAR\u03b3 signaling and metabolism: the good, the bad and the future. Nat Med. 2013, 19:557-66. 10.1038\/nm.3159","journal-title":"Nat Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.11.026","article-title":"The many faces of PPARgamma","volume":"123","author":"Lehrke M","year":"2005","unstructured":"Lehrke M, Lazar MA. The many faces of PPARgamma. Cell. 2005, 123:993-9. 10.1016\/j.cell.2005.11.026","journal-title":"Cell"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90006-x","article-title":"Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor","volume":"79","author":"Tontonoz P","year":"1994","unstructured":"Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 1994, 79:1147-56. 10.1016\/0092-8674(94)90006-x","journal-title":"Cell"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20 Suppl 1","author":"Nauck MA","year":"2018","unstructured":"Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018, 20 Suppl 1:5-21. 10.1111\/dom.13129","journal-title":"Diabetes Obes Metab"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3351","article-title":"Regulation of glucose transport by insulin: traffic control of GLUT4","volume":"13","author":"Leto D","year":"2012","unstructured":"Leto D, Saltiel AR. Regulation of glucose transport by insulin: traffic control of GLUT4. Nat Rev Mol Cell Biol. 2012, 13:383-96. 10.1038\/nrm3351","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath MY","year":"2011","unstructured":"Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011, 11:98-107. 10.1038\/nri2925","journal-title":"Nat Rev Immunol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.3110pe7","article-title":"ER stress in pancreatic beta cells: the thin red line between adaptation and failure","volume":"3","author":"Eizirik DL","year":"2010","unstructured":"Eizirik DL, Cnop M. ER stress in pancreatic beta cells: the thin red line between adaptation and failure. Sci Signal. 2010, 3:pe7. 10.1126\/scisignal.3110pe7","journal-title":"Sci Signal"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.02.034","article-title":"Endoplasmic reticulum stress and the inflammatory basis of metabolic disease","volume":"140","author":"Hotamisligil GS","year":"2010","unstructured":"Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell. 2010, 140:900-17. 10.1016\/j.cell.2010.02.034","journal-title":"Cell"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/nature21363","article-title":"Inflammation, metaflammation and immunometabolic disorders","volume":"542","author":"Hotamisligil GS","year":"2017","unstructured":"Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017, 542:177-85. 10.1038\/nature21363","journal-title":"Nature"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1126\/science.1103160","article-title":"Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes","volume":"306","author":"Ozcan U","year":"2004","unstructured":"Ozcan U, Cao Q, Yilmaz E, et al.. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004, 306:457-61. 10.1126\/science.1103160","journal-title":"Science"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1126\/science.1209038","article-title":"The unfolded protein response: from stress pathway to homeostatic regulation","volume":"334","author":"Walter P","year":"2011","unstructured":"Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science. 2011, 334:1081-6. 10.1126\/science.1209038","journal-title":"Science"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkad944","article-title":"The IUPHAR\/BPS guide to Pharmacology in 2024","volume":"52","author":"Harding SD","year":"2024","unstructured":"Harding SD, Armstrong JF, Faccenda E, et al.. The IUPHAR\/BPS guide to Pharmacology in 2024. Nucleic Acids Res. 2024, 52:D1438-49. 10.1093\/nar\/gkad944","journal-title":"Nucleic Acids Res"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkt1031","article-title":"The ChEMBL bioactivity database: an update","volume":"42","author":"Bento AP","year":"2014","unstructured":"Bento AP, Gaulton A, Hersey A, et al.. The ChEMBL bioactivity database: an update. Nucleic Acids Res. 2014, 42:D1083-90. 10.1093\/nar\/gkt1031","journal-title":"Nucleic Acids Res"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv352","article-title":"ChEMBL web services: streamlining access to drug discovery data and utilities","volume":"43","author":"Davies M","year":"2015","unstructured":"Davies M, Nowotka M, Papadatos G, et al.. ChEMBL web services: streamlining access to drug discovery data and utilities. Nucleic Acids Res. 2015, 43:W612-20. 10.1093\/nar\/gkv352","journal-title":"Nucleic Acids Res"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart DS","year":"2018","unstructured":"Wishart DS, Feunang YD, Guo AC, et al.. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018, 46:D1074-82. 10.1093\/nar\/gkx1037","journal-title":"Nucleic Acids Res"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1809937","article-title":"The \"All of Us\" Research Program","volume":"381","author":"Denny JC","year":"2019","unstructured":"Denny JC, Rutter JL, Goldstein DB, Philippakis A, Smoller JW, Jenkins G, Dishman E. The \"All of Us\" Research Program. N Engl J Med. 2019, 381:668-76. 10.1056\/NEJMsr1809937","journal-title":"N Engl J Med"},{"key":"ref41","article-title":"Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers","volume":"216","author":"Hripcsak G","year":"2015","unstructured":"Hripcsak G, Duke JD, Shah NH, et al.. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015, 216:574-8.","journal-title":"Stud Health Technol Inform"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.89","article-title":"Development of a large-scale de-identified DNA biobank to enable personalized medicine","volume":"84","author":"Roden DM","year":"2008","unstructured":"Roden DM, Pulley JM, Basford MA, Bernard GR, Clayton EW, Balser JR, Masys DR. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther. 2008, 84:362-9. 10.1038\/clpt.2008.89","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/510524-multi-ancestry-transcriptome-wide-association-study-twas-informed-prioritization-of-antipsychotic-metabolic-risk-evaluation-of-glp1r-as-a-shared-mechanistic-link","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T07:04:23Z","timestamp":1784185463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/510524-multi-ancestry-transcriptome-wide-association-study-twas-informed-prioritization-of-antipsychotic-metabolic-risk-evaluation-of-glp1r-as-a-shared-mechanistic-link"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":42,"URL":"https:\/\/doi.org\/10.7759\/cureus.112759","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,16]]}}}